Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

John P. Morris

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7275-6796; OpenAlex author ID A5086696426; NIH RePORTER profile ID 12329495. Sources: funder_awards.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
3
Labs led
0
Collaborators
56
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 4 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 grant · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 2 grants

Papers 11

  1. Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-1757↗
  2. p53 and YAP/TAZ-TEAD activities determine metaplastic heterogeneity in pancreatic cancer Last author DOI 10.64898/2025.12.11.693520↗
  3. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance. Co-author DOI 10.1038/s43018-023-00553-8↗
  4. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.05.010↗
  5. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Co-author DOI 10.1016/j.cell.2014.01.066↗
  6. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncb2916↗
  7. A modular and flexible ESC-based mouse model of pancreatic cancer. Co-author DOI 10.1101/gad.232082.113↗
  8. Dicer regulates differentiation and viability during mouse pancreatic cancer initiation. Co-author DOI 10.1371/journal.pone.0095486↗
  9. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-2067↗
  10. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccr.2012.10.025↗
  11. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Co-author DOI 10.1016/j.ccr.2011.03.002↗

Grants 3

  1. Identifying immune-mediated mechanisms of RAS inhibitor efficacy and resistance in pancreatic cancer AWARD pancan:2026-john-p-morris-iv-phd-identifying-immune-mediated-mechanisms-o
  2. Identifying immune-mediated mechanisms of RAS inhibitor efficacy and resistance in pancreatic cancer R21CA309360↗
  3. Dissecting Malignant Evolution Unleashed by p53 Inactivation in PDAC AWARD pancan:2021-john-morris-iv-phd-dissecting-malignant-evolution-unleashed

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Justin Milner · 1 shared grant, 2026 · strength 1.26
  2. Channing J. Der · 3 shared papers, 2020–2025 · strength 0.52
  3. Scott W. Lowe · 4 shared papers, 2014–2023 · strength 0.28
  4. Cole P Martin · 1 shared paper, 2025 · strength 0.26
  5. A. Cole Edwards · 1 shared paper, 2025 · strength 0.26
  6. Jonathan M. DeLiberty · 1 shared paper, 2025 · strength 0.19
  7. Kristina Drizyte‐Miller · 1 shared paper, 2025 · strength 0.19
  8. Emanuel F. Petricoin · 1 shared paper, 2025 · strength 0.19
  9. Kirsten L. Bryant · 1 shared paper, 2025 · strength 0.19
  10. Adrienne D. Cox · 1 shared paper, 2025 · strength 0.19
  11. Sarah E. Ackermann · 1 shared paper, 2025 · strength 0.19
  12. Ryan N. Robb · 1 shared paper, 2025 · strength 0.19
  13. Clint A. Stalnecker · 1 shared paper, 2025 · strength 0.19
  14. Mallory K. Roach · 1 shared paper, 2025 · strength 0.19
  15. Matthias Hebrok · 5 shared papers, 2011–2014 · strength 0.16
  16. Loretah Chibaya · 1 shared paper, 2023 · strength 0.14
  17. Marcus A. Ruscetti · 1 shared paper, 2023 · strength 0.14
  18. Chaitanya Naimesh Parikh · 1 shared paper, 2023 · strength 0.14
  19. Guido von Figura · 3 shared papers, 2012–2014 · strength 0.10
  20. Andrew Victor Biankin · 2 shared papers, 2014–2020 · strength 0.10
  21. Grace Kim · 3 shared papers, 2011–2014 · strength 0.10
  22. Fong Cheng Pan · 2 shared papers, 2012–2020 · strength 0.10
  23. Michael Saborowski · 2 shared papers, 2014 · strength 0.08
  24. Chun‐Hao Pan · 1 shared paper, 2020 · strength 0.07
  25. Peter J. Bailey · 1 shared paper, 2020 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.